Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -17.42 is 17% above its 5-year average of -21.03, around the middle of its 5-year range (-29.60–-9.90).
33.12% above its 12-month average of -26.05.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.33.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 28 comparable quarters.
EARNINGS PER SHARE (EPS)
-17.42
EARNINGS PER SHARE (EPS) AVG TTM
-26.05
EARNINGS PER SHARE (EPS) AVG 3Y
-23.35
EARNINGS PER SHARE (EPS) AVG 5Y
-21.03
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+33.12%
CURRENT VS 3Y AVG
+25.39%
CURRENT VS 5Y AVG
+17.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sutro Biopharma, Inc.
Market Cap
$141.87M
Earnings Per Share (EPS)
-17.42
TTM Avg
-26.05
3Y Avg
-23.35
5Y Avg
-21.03
Market Cap
$142.96M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$143.10M
Earnings Per Share (EPS)
-2.52
TTM Avg
-2.32
3Y Avg
-1.91
5Y Avg
-1.63
Market Cap
$140.46M
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.66
3Y Avg
-1.77
5Y Avg
-1.60
Market Cap
$143.51M
Earnings Per Share (EPS)
-1.36
TTM Avg
-1.75
3Y Avg
-3.23
5Y Avg
-3.64
Market Cap
$138.93M
Earnings Per Share (EPS)
-1.11
TTM Avg
-1.59
3Y Avg
-2.87
5Y Avg
-3.93
Market Cap
$144.33M
Earnings Per Share (EPS)
-12.04
TTM Avg
-8.05
3Y Avg
-55.02
5Y Avg
-123.25
Market Cap
$137.57M
Earnings Per Share (EPS)
-0.04
TTM Avg
-0.09
3Y Avg
-0.17
5Y Avg
-0.13
Market Cap
$137.40M
Earnings Per Share (EPS)
-3.85
TTM Avg
-4.48
3Y Avg
-4.48
5Y Avg
-4.48
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $141.87M | -17.42 | -26.05 | -23.35 | -21.03 |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.96M | 2.68 | -1.38 | -6.44 | -7.90 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -2.52 | -2.32 | -1.91 | -1.63 |
| Immuneering Corporation (IMRX)vs › | $140.46M | -1.04 | -1.66 | -1.77 | -1.60 |
| Protara Therapeutics, Inc. (TARA)vs › | $143.51M | -1.36 | -1.75 | -3.23 | -3.64 |
| Alpha Cognition Inc (ACOG)vs › | $138.93M | -1.11 | -1.59 | -2.87 | -3.93 |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.33M | -12.04 | -8.05 | -55.02 | -123.25 |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | -0.04 | -0.09 | -0.17 | -0.13 |
| Atrium Therapeutics, Inc. (RNA)vs › | $137.40M | -3.85 | -4.48 | -4.48 | -4.48 |
| Organigram Global Inc. (OGI)vs › | $136.58M | 0.45 | -0.23 | -0.84 | -0.86 |
Trailing EPS (TTM)
$-17.42
Forward EPS (Est.)
$-8.03
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -22.49 |
| 2024-12-31 | -29.60 |
| 2023-12-31 | -17.80 |
| 2022-12-31 | -23.50 |
| 2021-12-31 | -22.90 |
| 2020-12-31 | -9.90 |
| 2019-12-31 | -24.30 |
| 2018-12-31 | -15.50 |
| 2017-12-31 | -28.10 |
| 2016-12-31 | 38.60 |
